Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589408 | 1.00 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2TSHRSMN1; SMN2 | |
| SCHEMBL589407 | 1.00 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2TSHRSMN1; SMN2 | |
| SCHEMBL9777204 | 0.83 | NPSR1 (0.48) | HCAR2SMN1; SMN2 | |
| SCHEMBL17469589 | 0.83 | NPSR1 (0.48) | HCAR2SMN1; SMN2 | |
| SCHEMBL9718471 | 0.83 | ALDH1A1 (0.41) | HCAR2KEAP1NFE2L2SMN1; SMN2 | |
| SCHEMBL9718465 | 0.83 | ALDH1A1 (0.41) | HCAR2KEAP1NFE2L2SMN1; SMN2 | |
| SCHEMBL9777200 | 0.83 | NPSR1 (0.48) | HCAR2SMN1; SMN2 | |
| SCHEMBL9718475 | 0.83 | ALDH1A1 (0.41) | HCAR2KEAP1NFE2L2SMN1; SMN2 | |
| SCHEMBL4147346 | 0.81 | — | — | |
| SCHEMBL1427568 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220747-A2 | FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-3087067-B1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-24 | — | — | EP | disclosed |
| US-9624170-B2 | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624170-B2 | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160318864-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-03 | — | — | US | disclosed |
| US-20160318864-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-03 | — | — | US | disclosed |
| EP-3087067-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015099196-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015099196-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-02 | — | — | WO | disclosed |
| US-8334282-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-4906759-A | Process for the production of 4-alkoxy-2(5H) thiophenones | LONZA LTD. (CH) | 1990-03-06 | — | — | US | disclosed |
| EP-0346852-A2 | Process for producing 4-chloro-3-alkoxybut-2E-ene acid alkyl esters | LONZA AG (CH) | 1989-12-20 | — | — | EP | disclosed |
| US-4880940-A | 4-alkoxy-3-pyrrolin-2-on-1-yl acetic acid alkyl esters | LONZA LTD. (CH) | 1989-11-14 | — | — | US | disclosed |
| EP-0302240-A1 | Method of making a multilayer protective and/or decorative coating and water diluable coating compositions | BASF Lacke + Farben AG (DE) | 1989-02-08 | — | — | EP | disclosed |
| EP-0301300-A1 | Process for the preparation of a multilayer protective and/or decorative coating and water-dilutable coating compositions | BASF Lacke + Farben AG (DE) | 1989-02-01 | — | — | EP | disclosed |
| EP-0301398-A2 | Process for producing N-[(4-hydroxy-pyrrolidin-2-on-1-yl)-acetyl]-glycinamide | LONZA AG (CH) | 1989-02-01 | — | — | EP | disclosed |
| US-4788294-A | Process for the production of 4-alkoxy-3-pyrrolin-2-ones | LONZA LTD. (CH) | 1988-11-29 | — | — | US | disclosed |
| US-4780545-A | Production of 4-alkoxy-3-pyrrolin-2-on-1-yl acetic acid alkyl esters | LONZA LTD. (CH) | 1988-10-25 | — | — | US | disclosed |
| EP-0261668-A1 | Process for the preparation of 4-alkoxy-2(5H) thiophenones | LONZA AG (CH) | 1988-03-30 | — | — | EP | disclosed |
| EP-0216324-A2 | 4-Alkoxy-3-pyrrolin-2-one-1-yl-acetic acid alkyl and benzyl esters and their preparation | LONZA AG (CH) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318864-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, PNLIP, LYPLAL1 | HCAR2 2528/4885KEAP1 622/4885NFE2L2 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.